Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
Lukacs
Gergely L
GL
Program in Cell Biology, Research Institute, Hospital for Sick Children, Toronto.
Durie
Peter R
PR
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001692:Biological Transport; D018118:Chloride Channels / Q000378:metabolism; D018389:Codon, Nonsense / Q000187:drug effects; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects* / Q000235:genetics*; D005839:Gentamicins / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007473:Ion Channels; D009154:Mutation / Q000187:drug effects
D000900:Anti-Bacterial Agents; C505032:CFTR protein, human; D018118:Chloride Channels; D018389:Codon, Nonsense; D005839:Gentamicins; D007473:Ion Channels; D019005:Cystic Fibrosis Transmembrane Conductance Regulator